Orencia (abatacept) becomes the first drug to be approved to prevent GvHD, a condition in which donor immune cells attack tissues in the patient receiving an HSCT, commonly known as a bone marrow ...

US-based biopharmaceutical company Kashiv Biosciences has reported that a Phase I trial of its 125mg/mL pre-filled syringe ...